|
Video: What is a Stock Split?
|
|
Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase. According to our Bicycle Therapeutics stock split history records, Bicycle Therapeutics has had 0 splits. | |
|
Bicycle Therapeutics (BCYC) has 0 splits in our Bicycle Therapeutics stock split history database.
Looking at the Bicycle Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Bicycle Therapeutics shares, starting with a $10,000 purchase of BCYC, presented on a split-history-adjusted basis factoring in the complete Bicycle Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/24/2019 |
|
End date: |
05/03/2024 |
|
Start price/share: |
$13.05 |
|
End price/share: |
$24.58 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
88.35% |
|
Average Annual Total Return: |
13.65% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$18,834.52 |
|
Years: |
4.95 |
|
|
|
|
|